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ABSTRACT
Lower motor neuron (LMN) syndromes typically present
with muscle wasting and weakness and may arise from
pathology affecting the distal motor nerve up to the level
of the anterior horn cell. A variety of hereditary causes
are recognised, including spinal muscular atrophy, distal
hereditary motor neuropathy and LMN variants of
familial motor neuron disease. Recent genetic advances
have resulted in the identiﬁcation of a variety of disease-
causing mutations. Immune-mediated disorders,
including multifocal motor neuropathy and variants of
chronic inﬂammatory demyelinating polyneuropathy,
account for a proportion of LMN presentations and are
important to recognise, as effective treatments are
available. The present review will outline the spectrum of
LMN syndromes that may develop in adulthood and
provide a framework for the clinician assessing a patient
presenting with predominantly LMN features.
INTRODUCTION
Lower motor neuron (LMN) syndromes are clinic-
ally characterised by muscle atrophy, weakness and
hyporeﬂexia without sensory involvement. They
may arise from disease processes affecting the
anterior horn cell or the motor axon and/or its sur-
rounding myelin. Neuromuscular junction path-
ology and muscle disorders may mimic a LMN
disorder and form part of the differential diagnosis.
LMN syndromes can be broadly classiﬁed as
hereditary, sporadic or immune-mediated.
Immune-mediated neuropathies, such as multifocal
motor neuropathy (MMN) and chronic inﬂamma-
tory demyelinating polyneuropathy (CIDP) are
important to distinguish from sporadic and heredi-
tary forms, as treatments are available. LMN pre-
sentations of motor neuron disease (MND) are
most often sporadic, but several genetic mutations
have been described which can be associated with
LMN preponderance. Other hereditary forms of
LMN syndromes include the spinal muscular atro-
phies (SMAs) and distal hereditary motor neuropa-
thies (dHMNs). The increasing availability of
next-generation sequencing (NGS), including the
ability for multiple genes to be sequenced in paral-
lel, has resulted in an increase in the discovery of
novel genetic mutations.
The clinical evaluation of a patient presenting
with a LMN syndrome includes a thorough assess-
ment of disease onset and progression. This is par-
ticularly important to ascertain as a rapid rate of
decline may support a diagnosis of MND and
remains an important factor in distinguishing
MND from other relatively indolent conditions,
such as SMA and immune neuropathies. The
pattern of weakness should be documented, includ-
ing (1) symmetry versus asymmetry, (2) proximal
versus distal involvement, (3) upper versus lower
limb predominance and (4) presence versus absence
of bulbar involvement. Nerve conduction studies
and electromyography (EMG) are essential to
conﬁrm that the disorder is neurogenic and should
focus on assessing (1) the pattern of involvement,
including symmetry and length dependence, (2)
presence of focal motor conduction block or
demyelinating features and (3) the presence or
absence of subclinical sensory abnormalities.
Imaging, genetic testing, antibody markers and
advanced neurophysiological techniques are useful
adjuncts and form an extension of the clinical
assessment. The present review will examine LMN
syndromes from a clinical perspective as well as
providing an overview of current understanding of
pathophysiological mechanisms.
Late-onset SMA
SMA represents a group of genetic disorders result-
ing in the degeneration of anterior horn cells in the
spinal cord and motor nuclei in the brainstem
causing progressive, predominantly proximal
muscle weakness with reduced or absent reﬂexes.
They are classiﬁed into four types on the basis of
age of onset and clinical course (SMA I–IV).1 SMA
I and II are deﬁned by onset in infancy. SMA III is
a milder phenotype with signs of weakness present-
ing at or after 1 year of age with patients attaining
the ability to walk unaided.1 It is associated with
signiﬁcant variability in the age of onset, disease
progression and ambulatory period with some
patients only developing walking difﬁculties in
adulthood.2 Adult-onset SMA (SMA IV) typically
presents in the third or fourth decade of life with a
slowly progressive and relatively benign course.3
Respiratory insufﬁciency may occur in SMA IV, but
is usually mild and life expectancy is normal.1
The vast majority of SMA is autosomal recessive
(AR) in inheritance and related to mutations in the
SMN1 gene located on chromosome 5q13. Most
cases are homozygous for a deletion of exon 7
(94%), but a small percentage are compound het-
erozygous for a deletion in SMN1 and an intragenic
mutation of SMN1.4 Targeted molecular genetic
testing is the ﬁrst-line investigation for SMA to
detect homozygous deletions of SMN1 exon 7
gene. However, if only a single deletion is detected,
sequencing the SMN1 gene should be performed to
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assess for a point mutation. Overall, 4–5% of patients with clin-
ically typical SMA have no identiﬁable mutation in SMN1.5
Non-5q SMA can be inherited in an autosomal dominant (AD),
AR or X-linked pattern with marked clinical and genetic hetero-
geneity. NGS technology has facilitated the discovery of a
number of non-5q causative genes associated with SMA.6
Spinobulbar muscular atrophy (Kennedy’s disease)
Spinobulbar muscular atrophy or Kennedy’s disease is the most
common adult-onset SMA. It is a polyglutamine genetic dis-
order caused by a CAG trinucleotide repeat expansion in the
androgen receptor gene on the X-chromosome.7 Degeneration
of motor neurons in the spinal cord and brainstem results in a
slowly progressive disorder characterised by weakness and
atrophy of facial, bulbar and limb muscles without upper motor
neuron (UMN) signs (ﬁgure 1). Cramps, leg weakness, tremor
and orolingual fasciculations (see online supplementary video
S1) with bulbar symptoms are the most common presenting
symptoms. The syndrome affects only men, although female
carriers may experience mild symptoms such as cramps.8
Symptom onset is typically between 30 and 50 years of age, but
there is marked variability in age of presentation.9 Weakness is
typically noted ﬁrst in the lower limbs and may be symmetrical
or asymmetrical, affecting proximal and/or distal muscles.9 A
sensory neuropathy is commonly associated with the syndrome
and is usually subclinical. Associated androgen resistance may
result in gynaecomastia, testicular atrophy and oligospermia.
The diagnosis is conﬁrmed through molecular genetic testing
with affected men having >39 CAG repeats.10 Life expectancy
may be reduced in selected patients, most commonly due to
pneumonia resulting from bulbar dysfunction.9
Distal hereditary motor neuropathies
The dHMNs share the characteristics of a slowly progressive,
length-dependent (ie, distal predominant) pattern of LMN
weakness.11 They represent a genetically heterogeneous group
with signiﬁcant variability and overlap in clinical phenotypes for
many of the known implicated genes. Most are inherited in an
AD pattern, but AR and X-linked inheritance patterns have also
been described.12 Onset is often in childhood or teens, but
adult onset is not uncommon. Upper limb predominance
(dHMN V), vocal cord paralysis (dHMN type VII), respiratory
distress (dHMN type VI) and pyramidal signs may be associated
features in some patients. Signiﬁcant sensory involvement is
absent, allowing differentiation from axonal forms of
Charcot-Marie-Tooth disease, although some mutations may
cause both phenotypes.11
Despite signiﬁcant advances in molecular genetics, a disease-
causing mutation is only identiﬁed in ∼15% of patients with a
typical presentation of dHMN.13 Mutations in the HSPB1,
HSPB8 and BSCL2 genes are the most frequent causes of AD
dHMN. Mutations in HSPB1 and HSPB8 are associated with a
classical length-dependent motor neuropathy beginning in the
lower limbs which may present in childhood (dHMN type I) or
adulthood (dHMN type II).14 Several phenotypes associated
with mutations in BSCL2 have been described and include (1)
dHMN type II with a length-dependent motor neuropathy, (2)
dHMN V presenting with a predominantly upper limb distal
phenotype, (3) dHMN with pyramidal signs and (4) Silver syn-
drome with atrophy of the intrinsic hand muscles, pyramidal
signs and lower limb spasticity.14 The upper limb-onset pheno-
type (dHMN V) may also result from mutations in GARS with
most cases presenting in their second decade with progressive
weakness and wasting of the thenar eminence and ﬁrst dorsal
interossei muscles.15 Cramping and pain in the hands on expos-
ure to cold may be an early manifestation.15 The GARS mutation
may also present with a classical length-dependent neuropathy
beginning in the lower limbs, further highlighting the variabi-
lity in genotype–phenotype correlations. It remains unclear why
mutations in ubiquitously expressed proteins may result in such
variable and ‘focal’ phenotypes.11 Bulbar involvement is rare in
dHMN, but vocal paralysis secondary to recurrent laryngeal
nerve involvement is a feature of dHMN type VII which may
result from mutations in dynactin (DCTN1) SLC5A7 or
TRPV4.11 AR forms of dHMN are less common but there are
increasing numbers of genes being described for this group.11
Although targeted molecular genetic testing was the standard
approach to genetic testing in the past, NGS has become a more
efﬁcient and cost-effective means of establishing a diagnosis in
many settings. This is particularly true with many LMN syn-
dromes as there is a large overlap between genotypes and phe-
notypes. For example, individual genes can cause phenotypes
that have been labelled dHMN, amyotrophic lateral sclerosis
(ALS) and hereditary spastic paraplegia. Targeted gene panels
covering a large number of genes causing these phenotypes are
the current preferred NGS diagnostic test. Whole exome and
whole genome sequencing which sequence genes encoding pro-
teins, or an individual’s entire DNA, respectively, are commonly
used in research and increasingly in diagnostic testing and may
have particular clinical utility when known suspected genes have
been tested by other methods and found to be normal. Such
advances in neurogenetics may allow a genetic diagnosis to be
established in a greater proportion of patients, but challenges
remain including difﬁculties managing large volumes of data, in
the interpretation of sequence variants and determining the
pathogenicity of detected mutations. Furthermore, NGS may
result in failure to detect certain mutations such as chromosomal
deletions or insertions and repeat expansions.
Immune-mediated neuropathies
Several immune-mediated neuropathies may present with a
purely motor or motor-predominant neuropathy and can be
divided into acute and chronic forms. They are important to dif-
ferentiate from hereditary and degenerative causes as they may
respond to immunotherapy. The acute immune-mediated neuro-
pathies are collectively referred to as Guillain-Barré syndrome
(GBS) with a number of variants described including a motor
variant known as acute motor axonal neuropathy (AMAN).
Chronic forms of the immune-mediated neuropathies include
MMN and CIDP.
Figure 1 Spinobulbar muscular atrophy (Kennedy’s disease): (A) facial
asymmetry due to asymmetrical facial muscle weakness which is
accentuated by pursing the lips; (B) tongue wasting resulting in
scalloping of the lateral borders and midline furrowing.
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Guillain-Barré syndrome
GBS may present as a pure motor disorder. Both the classic
acute inﬂammatory demyelinating polyneuropathy (AIDP) form
and the recently described AMAN can be pure motor, although
the latter is deﬁned by its pure motor phenotype and axonal
characteristics. Clinically, AMAN is part of the GBS spectrum
but distinguished by normal sensation and nerve conduction
studies characterised by low distal motor evoked amplitudes,
normal sensory conductions and no features of demyelination.
Prognosis is similar to that seen in the AIDP form of GBS unless
there is secondary axonal degeneration in which case, like in the
AIDP form, recovery is delayed. There is a strong association
between AMAN and IgG antibodies against GM1 or GD1a
which may be a result of molecular mimicry resulting from ante-
cedent Campylobacter jejuni infection.16
Chronic immune-mediated neuropathies
MMN typically presents with asymmetrical distal weakness and
wasting, without sensory impairment which is slowly progres-
sive and has an upper limb predilection17 (ﬁgure 2). Weakness
may be out of proportion to muscle wasting and involvement of
wrist and/or ﬁnger extension at onset should prompt consider-
ation of MMN as a potential diagnosis. Positive features such as
twitching, cramping and spasm are relatively common in MMN
and may be the presenting symptom.18 Bulbar and respiratory
involvement are not typical, although respiratory symptoms may
occur due to phrenic nerve involvement.
A deﬁnitive diagnosis of MMN requires demonstration of
focal motor conduction block on neurophysiological studies
with normal sensory nerve conduction across the region of
block.19 As conduction block may be difﬁcult to demonstrate
and may occur in proximal segments, comprehensive neuro-
physiology should be performed and proximal stimulation may
be required. A normal compound muscle action potential ampli-
tude in a weak muscle with neurogenic recruitment on EMG
suggests the presence of conduction block. Anti-GM1 IgM is
present in ∼50% of cases with a high titre supporting a diagno-
sis of MMN.17 MRI may reveal asymmetrical nerve enlargement
and increased signal intensity on T2-weighted images of the bra-
chial plexus.20 Ultrasound imaging may show multiple sites of
peripheral nerve enlargement in the arms, including segments
without conduction abnormalities.21
Intravenous immunoglobulin (IVIg) is the accepted treatment
for MMN.17 Dosing must be individualised and no optimal
dosing strategy has been established, although high doses of
IVIg are often required.22 Furthermore, despite treatment,
MMN is often associated with progressive axonal loss and func-
tional decline.17
A purely ‘axonal’ form of MMN has been described which
lacks demonstrable partial motor conduction block, demyelinat-
ing features and anti-GM1 antibodies, but may respond to
IVIg.23 It is important to recognise, however, that at least some
of the ‘apparent’ cases of ‘axonal MMN’ may represent MMN
with very proximal conduction blocks which are not detectable
with standard neurophysiological techniques.24 A trial of IVIg
may be warranted in select cases of asymmetrical adult-onset
LMN syndromes without demonstrable conduction block, par-
ticularly those with distal upper limb-onset weakness.25 A pure
motor variant of CIDP with sparing of sensory ﬁbres clinically
and neurophysiologically has also been reported. As in MMN,
the neuropathy appears to be responsive to IVIg, but not corti-
costeroids, which may cause deterioration.26
Motor neuron disease
MND is widely recognised as a fatal heterogeneous group of
neurodegenerative disorders. The combination of upper and
LMN signs is the pathognomonic hallmark with this variant
referred to as ALS. Pure UMN and LMN forms have also been
described representing opposite clinical ends of the MND
spectrum.27
Progressive muscular atrophy
The LMN phenotype of MND (progressive muscular atrophy,
PMA) is characterised by progressive LMN signs without clinical
evidence of UMN dysfunction, although a signiﬁcant proportion
develop UMN signs during the disease course.28 It is estimated
that the syndrome represents ∼5% of MND cases, and may be
characterised by slower progression than other forms of
MND.28 In the absence of UMN signs, conﬁdent differentiation
from other LMN syndromes may be difﬁcult, often requiring a
Figure 2 Asymmetric wasting of thenar eminence in a 71-year-old male with an upper limb predominant motor neuropathy associated with
anti-GM1 IgM antibody (A). High doses of intravenous immunoglobulin were required to achieve disease stabilisation. The CMAP was unrecordable
on the right from APB. The distal APB CMAP on the left was normal, but there was marked dispersion and reduction in CMAP amplitude with
stimulation at the elbow (B). A, amplitude; A, area; APB, abductor pollicis brevis; d, duration; CMAP, compound muscle action potential; CV,
conduction velocity; NCS, nerve conduction studies.
Garg N, et al. J Neurol Neurosurg Psychiatry 2016;0:1–10. doi:10.1136/jnnp-2016-313526 3
Neuromuscular
group.bmj.com on May 18, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
period of observation to assess progression. The novel neuro-
physiological technique of threshold tracking transcranial mag-
netic stimulation (TMS) has been a major advance allowing for
objective assessment of the functional integrity of the UMN
system.29 Threshold tracking TMS has demonstrated evidence
of cortical hyperexcitability in MND and may play a role in the
differentiation from mimic disorders by providing objective evi-
dence of UMN dysfunction when it is not evident clinically.30
Flail arm syndrome
The ﬂail arm syndrome (brachial amyotrophic diplegia or
‘man-in-the-barrel’ syndrome) is a distinct variant of MND char-
acterised by a progressive, predominantly LMN pattern of
weakness in the upper limbs, typically beginning in proximal
muscle groups with progression to distal involvement. Original
descriptions were of a symmetrical pattern of weakness, but
there may be some asymmetry, particularly early in the disease
course. Mild UMN signs are often present in the lower limbs.
There is a striking male predominance with a male-to-female
ratio of 4:1,31 and up to 10:1 in some series.32 Prognosis is
better than that of classical ALS with a median survival of
∼5 years.31 The ﬂail arm phenotype is associated with cortical
hyperexcitability with a similar pattern to that seen in ALS.32
Hence, TMS may be a useful adjunct in differentiating this
MND variant from other more benign LMN syndromes with
upper limb predominance.
Flail leg syndrome
The ﬂail leg variant of MND (also known as the pseudopoly-
neuritic variant) is characterised by a progressive, asymmetrical
predominantly LMN pattern of weakness with distal-onset
weakness and wasting of the lower limbs. UMN signs often
emerge over time.31 Progression is slower than classical ALS
with a median time of 33 months to involvement of a second
region and median survival of almost 6 years. In contrast to the
ﬂail arm variant, the ﬂail leg group show an equal
male-to-female ratio.31 As with other forms of MND, cortical
hyperexcitability is a feature of the ﬂail leg syndrome, but only
when UMN signs are present. In contrast, features of cortical
hyperexcitability were not demonstrated in patients who lacked
UMN signs on clinical examination.33
Familial LMN variants of MND
A variety of genetic mutations may be associated with signiﬁcant
LMN involvement with or without UMN signs. They include
mutations in copper–zinc superoxide dismutase type 1 (SOD1),
fused in sarcoma (FUS), vesicle-associated membrane protein/
synaptobrevin-associated membrane protein B (VAPB) and
chromatin-modifying protein 2b (CHMP2B) genes.34 Most of
the known forms are inherited in an AD pattern.
SOD1 gene mutations account for 20% of AD familial MND
and are the second most common cause of familial MND (fol-
lowing the expanded hexanucleotide repeat in the C9ORF72
gene associated with the ALS-frontotemporal dementia spec-
trum).27 The A4V missense mutation has been demonstrated to
occur in around 40% of patients with SOD1 mutations in
North American series and is rare in the European population.35
LMN signs predominate with absent or mild UMN features.
Disease progression is particularly rapid with a median survival
of 1.2 years from disease onset.35 The A4T mutation is also
associated with a similarly rapid disease course and LMN pre-
dominant syndrome.36 In contrast, the G93C mutation has been
associated with a pure LMN clinical phenotype without bulbar
involvement and more favourable prognosis with a median
survival of 153 months.37 The D101N mutation in exon 4 of
the SOD1 gene has been associated with PMA with limited
bulbar involvement and rapid disease course with mean time to
death from respiratory failure of 28 months.38
Mutations in the FUS gene account for ∼5% of familial
MND and may present with PMA or LMN predominant
MND.39 Mutations in the VAPB gene have been associated with
a range of phenotypes including PMA and late-onset SMA.40
Mutations in the CHMP2B gene were ﬁrst linked to frontotem-
poral dementia, but may be associated with PMA or ALS. In
one series, CHMP2B mutations were found in 10% of patients
with LMN predominant ALS, although most cases exhibited a
sporadic phenotype.41
Monomelic amyotrophy
Monomelic amyotrophy (MMA) is a LMN disorder that pre-
sents with insidious onset of focal wasting and weakness, most
commonly affecting the upper limb unilaterally, although it can
rarely affect a lower extremity. Symptoms typically progress over
a period of 1–5 years and then plateau.42 Bulbar, sensory and
pyramidal signs are absent. The condition has a striking male
predominance with a male-to-female ratio of 10:1.42 It is seen
more commonly in Asian countries with a median age of onset
in the late teens or early 20s.42
The typical pattern of weakness and wasting in upper extrem-
ity MMA (also known as Hirayama disease) is distal predomin-
ant affecting the hand and forearm muscles, with C7-T1
innervated muscles classically affected. Preservation of brachior-
adialis muscle bulk (a C6 innervated muscle) with wasting of C7
innervated forearm muscles may result in the clinical sign
described by Hirayama et al43 as ‘oblique amyotrophy’.
Symptoms may be aggravated by cold weather and there may be
an associated mild tremor on ﬁnger extension. Less severe
involvement of the contralateral upper limb may occur in a sig-
niﬁcant proportion of patients.42 MRI ﬁndings in Hirayama
disease may reveal lower cervical cord atrophy (C5–C7), asym-
metric cord ﬂattening and/or intramedullary hyperintensity.
Anterior displacement of the dorsal dura on neck ﬂexion may
be seen and venous plexus engorgement may give the appear-
ance of an enhancing epidural crescent along the posterior
aspect of the cord on neck ﬂexion views.44
Lower extremity MMA presents with weakness and wasting
of a unilateral lower limb, although less severe or subclinical
involvement of the contralateral limb may occur. It is less
common than Hirayama disease but is also characterised by
male predominance and benign course. Posterior leg muscles are
disproportionately affected with imaging studies demonstrating
most severe involvement of gastrocnemius and soleus muscles
with marked asymmetry.45 46 The degree of wasting may be out
of proportion to weakness and disability.45
Segmental lower motor neuron disease
While progression typically arrests within a few years in
Hirayama disease, segmental LMN disease is a localised form of
sporadic adult-onset LMN disease affecting the upper limbs char-
acterised by progression over a longer period extending up to
20 years.47 The clinical presentation is with asymmetrical LMN
signs localised to the upper extremities with unilateral domin-
ance. Both proximal and distal forms are recognised. The clinical
course is favourable with progression to generalised MND/ALS
rare. MRI may reveal a ‘snake eyes’ appearance with T2-signal
hyperintensity in the anterior horns of multiple segments of the
cervical cord, although this is a non-speciﬁc ﬁnding and has been
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associated with a number of other LMN syndromes including
cervical spondylosis and infection48 (ﬁgure 3).
Poliomyelitis and other infections
Poliomyelitis is a rare complication of poliovirus infection char-
acterised by the destruction of the anterior horn cells causing
motor weakness. Wild-type polio has largely been eradicated
and remains endemic only along the borders of Pakistan and
Afghanistan.49 The typical presentation is of acute ﬂaccid paraly-
sis which is asymmetrical and affects the lower limbs more fre-
quently than the upper limbs.50 Weakness is most prominent in
proximal muscle groups. Myalgias and muscle spasm are often
prominent prior to onset of weakness. Bulbar and respiratory
involvement may occur. PCR of the virus from cerebrospinal
ﬂuid is the gold standard for conﬁrming the diagnosis. Most
affected patients recover strength, although a signiﬁcant propor-
tion are left with some residual weakness.
Other enteroviruses (including coxsackievirus, echoviruses
and enterovirus 71) and the ﬂaviviruses, such as West Nile virus
may also cause acute ﬂaccid paralysis due to anterior horn cell
disease.50
Postpolio syndrome
Postpolio syndrome develops after a period of stability in a pro-
portion of patients who have recovered from acute poliomyel-
itis. Symptoms may include the development of new weakness
and muscle atrophy, fatigue and/or pain.50 The cause of postpo-
lio syndrome remains unclear and may be due to the degener-
ation of enlarged reinnervated motor units.
Other LMN syndromes
Although rare, lead and porphyric neuropathies are brieﬂy dis-
cussed here, as they are treatable causes of motor neuropathies.
Lead toxicity can lead to a subacute motor neuropathy which
Figure 3 This 46-year-old man presented with a 20-year history of progressive distal wasting and weakness of the right hand and forearm
muscles. Symptoms developed in the left hand 5 years prior to presentation. Upper limb reﬂexes were depressed. Needle electromyography revealed
chronic neurogenic changes in clinically affected muscles. There were no sensory abnormalities. (A and B) Asymmetrical wasting of the hands and
forearm affecting C7-T1 musculature with striking preservation of brachioradialis in the right upper limb; (C) sagittal T2-weighted STIR image
demonstrating a linear hyperintensity within the cervical cord at C6 and C7 associated with cord atrophy; (D) axial T2-weighted image with ‘snake
eyes’ appearance in the anterior horns. STIR, Short TI Inversion Recovery.
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Figure 4 Diagnostic algorithm for a patient presenting with a LMN syndrome. ALS, amyotrophic lateral sclerosis; CB, conduction block; dHMN, distal hereditary motor neuropathy; FHx, family history;
GBS, Guillain-Barré syndrome; LL, lower limb; LMN, lower motor neuron; MMA, monomelic amyotrophy; MMN, multifocal motor neuropathy; MND, motor neuron disease; NCS, nerve conduction studies;
NGS, next-generation sequencing; PMA, progressive muscular atrophy; SBMA, spinobulbar muscular atrophy; SMA, spinal muscular atrophy; UL, upper limb.
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classically affects the wrist and ﬁnger extensors before spreading
to other muscles and hence may be confused with MMN.51
Porphyria, an inherited metabolic disorder of heme biosynthesis,
may present with an acute or subacute predominantly motor
neuropathy also with focal weakness at onset, such as wristdrop
or footdrop. The acute onset may lead to confusion with
AMAN. Both lead and porphyric neuropathies are typically
associated with involvement of other organ systems and add-
itional features may include gastrointestinal symptoms, cognitive
disturbance and haematological changes.51 52 A family history
of symptoms of porphyria or history of occupational exposure
to lead may provide clues to the diagnosis. Lead toxicity is treat-
able with chelation and porphyria with haematin.
KEY DIFFERENTIATING FEATURES
The LMN syndromes represent a group of conditions with a
variety of presentations and varied underlying disease mechan-
isms. While a thorough clinical assessment and neurophysiology
can usually delineate or assist in classiﬁcation of the different
syndromes, peripheral nerve and muscle imaging and the
rapidly advancing ﬁeld of NGS are additional diagnostic tools
available to clinicians. Neurophysiological ﬁndings in the major-
ity of LMN syndromes consist of axonal loss with a reduction
in compound muscle action potential amplitudes with normal
or slightly reduced motor conduction velocities. In contrast,
ﬁndings suggestive of an immune-mediated motor neuropathy
include features such as signiﬁcantly reduced conduction veloci-
ties, focal partial motor conduction block and prolongation of
F-wave latencies. While treatments are currently limited for
most syndromes, immune-mediated LMN disorders may
respond to immunotherapy and hence are important to distin-
guish from hereditary and degenerative causes.
Figure 4 outlines a diagnostic approach for the patient pre-
senting with a LMN syndrome. Table 1 outlines the typical clin-
ical features of the different LMN syndromes. An acute
presentation of a LMN syndrome with onset over days to weeks
Table 1 Clinical features of LMN syndromes
Typical pattern of weakness
Symmetry Proximal/distal
Limb
predominance
Bulbar
involvement Disease progression Investigation findings
SMA Symmetrical Proximal>distal LL>UL Yes Slowly progressive Homozygous deletion exon 7 SMN1
gene (94%); small percentage
compound heterozygous for SMN1
deletion and an intragenic mutation
of SMN1
SBMA Symmetrical or
asymmetrical
Proximal>distal LL>UL Yes Slowly progressive X-linked trinucleotide CAG expansion
(>39 repeats) androgen receptor gene
dHMN Symmetrical Distal LL>UL; exception
dHMN V: UL
predominance
Rare; laryngeal
involvement in
dHMN VII
Slowly progressive Mutations in HSPB1, HSPB8, BSCL2,
GARS, DCTN1, TRP4, SETX
Immune GBS Symmetrical Distal>proximal UL and LL May occur Acute: weakness
usually progresses over
hours-days
Anti-GM1 IgG antibody and anti-
GD1a IgG antibody in AMAN variant
MMN Asymmetrical Distal>proximal UL No Slowly progressive Anti-GM1 IgM in 30–80%
CIDP (motor) Symmetrical or
asymmetrical
Proximal and
distal
UL and LL No Relapsing-remitting Anti-GM1 IgM often negative
MND (LMN
variants)
Sporadic Asymmetrical Distal>proximal Variable May occur ∼10% Median survival
3–4 years
Anti-GM1 IgM antibodies may be
present but typically low titre
Features of cortical hyperexcitability
on TMS
Flail arm Symmetrical Proximal>distal UL Not at onset; may
develop later in
disease course
Median survival ∼5 years
Flail leg Asymmetrical Distal>proximal LL Not at onset; may
develop later in
disease course
Median survival ∼6 years
Genetic Asymmetrical Variable Variable Variable Variable; rapid and
slowly progressive forms
described
Mutations in SOD1, FUS, VAPB, and
CHMP2B
MMA Asymmetrical Distal>proximal UL involvement
more frequent than
LL
No Insidious onset, slow
progression, followed by
stabilisation
MR findings: lower cervical cord
atrophy, asymmetric cord flattening,
and/or anterior displacement of the
dorsal dura on neck flexion
Segmental
LMN disease
Asymmetrical Distal or
proximal
UL No Insidious onset, slow
progression up to
20 years
MRI may reveal ‘snake eyes’
appearance
Polio Acute
poliomyelitis
Asymmetrical Proximal>distal LL>UL 5–35% of patients Acute: weakness
usually progresses over
hours-days
PCR poliovirus from CSF
Postpolio
syndrome
Asymmetrical Variable Variable Variable Slowly progressive;
fatigue and pain
common
Changes of chronic denervation with
reinnervation on needle
electromyography
AMAN, acute motor axonal neuropathy; CHMP2B, chromatin-modifying protein 2b; CIDP, chronic inflammatory demyelinating polyneuropathy; CSF, cerebrospinal fluid; dHMN, distal
hereditary motor neuropathy; FUS, fused in sarcoma; GBS, Guillain-Barré syndrome; LL, lower limb; LMN, lower motor neuron; MMA, monomelic amyotrophy; MMN, multifocal motor
neuropathy; MND, motor neuron disease; SBMA, spinobulbar muscular atrophy; SMA, spinal muscular atrophy; SOD1, superoxide dismutase type 1; TMS, transcranial magnetic
stimulation; UL, upper limb; VAPB, vesicle-associated membrane protein/synaptobrevin-associated membrane protein B.
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should prompt consideration of an immune, toxic, metabolic or
infective aetiology. The major differentials for a chronic mono-
melic or asymmetrical presentation include MND, MMN and
MMA. Early involvement of ﬁnger and wrist extensors, focal
motor conduction block on neurophysiology and/or the pres-
ence of anti-GM1 IgM antibody should prompt consideration
of MMN as the diagnosis and warrants a treatment trial of IVIg.
Positive symptoms, such as cramping and spasm are common in
MMN. In contrast, positive symptoms are rarely a prominent
presenting symptom in MND with negative features of LMN
dysfunction dominating.53
Monomelic weakness, particularly in a young man, with pro-
gression over several years followed by stabilisation may be indi-
cative of MMA, particularly if the sign of oblique amyotrophy or
typical MRI changes are present. The clinical distinction between
MMA and MND may be difﬁcult early in the disease course, and
tends to be determined by an extended period of clinical observa-
tion. It has been suggested that progression to MND should only
be excluded if there has been no progression beyond the upper
limb within 3 years.54 A similar timeframe could also be applied
to lower extremity MMA. The presence of cortical hyperexcit-
ability on threshold tracking TMS may be a helpful adjunct in dif-
ferentiating LMN-predominant MND from other LMN
disorders although the results must be interpreted in the context
of other clinical and neurophysiological ﬁndings. Furthermore,
EMG may reveal features of active denervation and/or reinnerva-
tion changes in clinically normal limbs in MND.
Although not always present, enquiry regarding recent or past
pain should be made as it may suggest compressive or inﬂamma-
tory causes, including spondylosis, brachial and lumbosacral
Figure 5 Proposed pathogenic mechanisms for LMN syndromes. LMN syndromes may arise from disease processes affecting the anterior horn cell
or the motor axon and/or its surrounding myelin. (A) A variety of mechanisms have been implicated in the degenerative and hereditary syndromes
including mitochondrial dysfunction, altered RNA processing and impaired axonal transport (see text for further details). (B) Anti-GM1 antibodies
may bind to GM1 in the paranodal region leading to disruption of ion channel clusters and paranodal anatomy. Although not a purely LMN
syndrome, IgG4 antibodies against NF155 and CNTN1 have recently been described and may similarly disrupt paranodal anatomy resulting in a
sensorimotor neuropathy. CNTN1, contactin-1; LMN, lower motor neuron; NF155, neurofascin-155.
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plexitis and neuritis. As cervical and lumbar spondylosis are
common conditions, imaging of the spine and brachial/lumbosa-
cral plexus should always be considered, particularly in patients
with asymmetrical involvement to exclude radiculopathy and to
assess for nerve root/plexus pathology which may suggest an
immune aetiology. Cervical spine MRI with neck ﬂexion views
should be considered when Hirayama’s disease is a differential
diagnosis.
A hereditary aetiology may be suspected by a history of slowly
progressive weakness with onset in childhood or early adulthood
and/or the presence of a positive family history. An insidious onset
of slowly progressive relatively symmetrical weakness over many
years is suggestive of dHMN when the pattern of weakness is
distal or SMA if weakness is predominantly proximal. Upper limb
predominance may indicate dHMN with a mutation in GARS or
BSCL2. Symmetrical weakness conﬁned to the upper limbs may
indicate the ﬂail arm variant of MND, but here the weakness typic-
ally begins in proximal muscle groups and extends distally with a
relatively progressive course. Slowly progressive asymmetrical
weakness over many years in a segmental pattern should prompt
consideration of segmental LMN disease. Bulbar involvement may
occur in MND and SMA but does not occur in MMA and is not
typical in MMN or dHMN.
PATHOPHYSIOLOGY
Pathogenic mechanisms of axonal degeneration and cell death in
the genetic LMN syndromes are a complex interaction of mul-
tiple factors (ﬁgure 5). Implicated mechanisms in dHMN
include protein misfolding and aggregate formation as well as
impaired axonal transport and RNA processing.55 Mutations in
the SMN1 gene causing SMA result in reduction in intracellular
survival motor neuron (SMN) protein levels. This is believed to
cause death of motor neurons in the spinal cord and lower
brainstem by interfering with RNA processing and spliceosome
assembly.56
Neurodegeneration in MND is postulated to occur through
multifactorial mechanisms including glutamate excitotoxicity,
axonal transport dysfunction, RNA processing defects, mito-
chondrial dysfunction and oxidative stress.27 57 58 SOD1 muta-
tions lead to abnormalities in protein degradation, resulting in
aggregate formation and triggering damage to axonal transport,
mitochondrial function and a variety of other cellular func-
tions.57 However, the precise mechanisms underlying
LMN-dominant presentations of MND remain unknown.
Similarly, the aetiology of LMN disorders with restricted
regions of involvement remains unclear. Pathological studies
have demonstrated focal degeneration restricted to anterior
horn cells in MMA.43 It has been postulated that upper extrem-
ity MMA may be a myelopathy related to ﬂexion movements of
the neck with resultant ischaemic damage to the anterior horn
cells of the cervical cord.44 Alternatively MMA may represent a
primary localised neurodegenerative disorder of the anterior
horn cell.
Pathophysiological mechanisms in immune-mediated neuro-
pathies reﬂect a different aetiology, involving aberrant cellular
and humoral immune responses. The site of pathology in MMN
is likely to lie in the region of the node of Ranvier and para-
node. It has been postulated that anti-GM1 antibodies may bind
to the ganglioside GM1 which is enriched in the paranodal
region, activating complement and leading to the disruption of
ion channel clusters and paranodal anatomy.17 59 It has been
suggested that GM1 is more abundant within motor than in
sensory nerves, resulting in the preferential motor selectivity
seen in MMN, although late sensory involvement has been
described.17 In contrast to MMN, antigenic targets in CIDP
remain largely elusive, although IgG4 antibodies against the
paranodal proteins neurofascin-155 and contactin-1 have
recently been described and are associated with a severe sensory
and motor CIDP phenotype with poor response to IVIg, but
favourable response to rituximab.60 61 Further delineation of
pathophysiological mechanisms underlying different LMN syn-
dromes will contribute to improved disease classiﬁcation and
the development of targeted treatments.
CONCLUSION
LMN syndromes represent a spectrum of disorders with a
variety of underlying aetiologies and presentations. Clinical
assessment combined with neurophysiology are often adequate
to establish a diagnosis, but advances in genetic and imaging
techniques are further diagnostic tools becoming increasingly
accessible to clinicians. Although establishing an accurate diag-
nosis in LMN presentations can be clinically challenging at
times, it is important due to prognostic and treatment
implications.
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